IceCure Medical gains after ProSense update, $5.5M placement
IceCure Medical soared 200.47% to $6.40 after reporting a 70% jump in U.S. ProSense breast cancer cryoablation installs post-FDA clearance and announcing a $5.5 million private placement at $3.00 per share with warrants, as investors weigh rapid adoption against dilution from new share supply.